Reserpine for the Treatment of Cocaine Dependence - 1
Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders; Substance-Related Disorders
Intervention: Reserpine (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s): Eugene Somoza, M.D., Ph.D., Principal Investigator, Affiliation: Cincinnati VA Medical Center
Summary
The purpose of this study is to assess the efficacy and safety of reserpine for the
treatment of cocaine dependence.
Clinical Details
Official title: Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Cocaine useAddiction severity Cocaine withdrawal Adverse events Clinical improvement
Detailed description:
To assess the efficacy and safety of reserpine in reducing cocaine use in subjects with
cocaine dependence. This is a double-blind, placebo-controlled, parallel-group design with a
2 week baseline period.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Be at least 18 yrs of age; DSM-4 diagnosis of cocaine dependence; treatment seeking
individuals; have the ability to understand and provide written informed consent; females
of child bearing potential using appropriate birth control method
Exclusion Criteria:
Additional criteria available during screening at the site.
Locations and Contacts
Boston University Medical Center, Boston, Massachusetts 02215, United States
Cincinnati VA Medical Center, Cincinnati, Ohio 45220, United States
Dayton VA Medical Center, Dayton, Ohio 45428, United States
Additional Information
Starting date: July 2001
Last updated: August 15, 2008
|